Abstract
BackgroundDrug-induced liver injury (DILI) is a common adverse event, which compromises the safety of numerous drugs, poses a significant risk to patient health, and enhances healthcare expenditures. Many articles have been recently published on DILI related research, though no relevant scientometric study has been published yet. This scientometric study was aimed at comprehensively analyzing the knowledge base and emerging topics on DILI.MethodsThe articles and reviews related to DILI, published from 2010 to 2019 in the Web of Science Core Collection (WoSCC), were retrieved on March 15, 2020, using relevant keywords. Four different scientometric software (HistCite, VOSviewer, CiteSpace, and R-bibliometrix) was used to conduct this scientometric study.ResultsA total of 1,995 publications were retrieved (including 1,550 articles and 445 reviews) from 592 academic journals with 56,273 co-cited references in 10 languages by 2,331 institutions from 79 countries/regions. The majority of publications (n = 727, 36.44%) were published in the United States, and the University of North Carolina contributed the most publications (n = 89, 4.46%). The most productive academic journal on DILI was the Toxicological Sciences [n = 79, 3.96%; impact factor (IF) 2018 = 3.564], and Hepatology was the first co-cited journal (n = 7,383, IF 2018 = 14.971). Fontana RJ and Teschke R may have significant influence on DILI research, with more publications (n = 46; n = 39) and co-citations (n = 382; n = 945). Definition, incidence rate or clinical characteristics, etiology or pathogenesis (such as the character of the innate immune system, the regulation of cell-death pathways, and susceptible HLA-B*5701 genotype), identification of main drugs and causality assessment (criteria and methods) were the knowledge base for DILI research. Exploring the microscopic mechanism (such as the organelle dysfunction and cytotoxicity induced by drugs, and exploration of role of neutrophils in DILI using mouse models) and developed newer approaches to prevent DILI (such as the prospective HLA-B*5701 screening and in vitro approaches for assessing the potential risk of candidate drugs for DILI) were the recent major topics for DILI research.ConclusionThis scientometric study comprehensively reviewed the publications related to DILI during the past decade using quantitative and qualitative methods. This information would provide references for scholars, researching on DILI.
Highlights
Drug-induced liver injury (DILI) is a common adverse event, which compromises the safety of numerous drugs and herbs, poses a significant risk to patient health, and enhances healthcare expenditures
We identified a total of 1,995 DILI studies, published between 2010 and 2019, including 1,550 articles and 445 reviews
Based on 2010–2019 data from Science Citation Index Expanded (SCIE) in WoSCC, a total of 1,995 papers were in 592 peer-reviewed journals with 56,273 co-cited references in 10 languages by 2,331 institutions from 79 countries/regions, and the scientometric study included the analysis of the research status, development tendencies, and hotspots of the DILI-related publications to offer the references to researchers
Summary
Drug-induced liver injury (DILI) is a common adverse event, which compromises the safety of numerous drugs and herbs, poses a significant risk to patient health, and enhances healthcare expenditures. In China, hepatotoxicity (induced by drugs, herbs, and toxins) comprises the majority of the cases of acute hepatic failure (Zhao et al, 2013). Chalasani et al collated all the information related to the cases of DILI during the last 10 years from the United States DILI Network (DILIN) (Chalasani et al, 2015). Drug-induced liver injury (DILI) is a common adverse event, which compromises the safety of numerous drugs, poses a significant risk to patient health, and enhances healthcare expenditures. This scientometric study was aimed at comprehensively analyzing the knowledge base and emerging topics on DILI
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
